Bronchogen for Respiratory Health & Bronchial Tissue Support — Bioregulators
Khavinson bioregulator peptide for bronchial and lung tissue regeneration, respiratory function optimization.
Overview
Bronchogen is a Khavinson peptide bioregulator consisting of short-chain peptides (2-4 amino acids) that interact directly with DNA in bronchial epithelial cells. Developed by Professor Vladimir Khavinson through 40+ years of research, bioregulators are organ-specific compounds that restore tissue-specific gene expression patterns to support cellular repair and regeneration. Bronchogen targets the respiratory system, particularly bronchial and lung tissue, to enhance respiratory function, support mucosal health, and promote tissue repair. Unlike traditional peptides that act on cell surface receptors, bioregulators bind to specific DNA sequences to regulate gene transcription epigenetically.
Indications
- Chronic bronchitis and respiratory conditions
- Bronchial tissue repair and regeneration
- Respiratory function optimization in aging
- Post-respiratory infection recovery
- COPD supportive therapy
- Environmental respiratory stress (pollution, smoking exposure)
- Athletic respiratory performance enhancement
Mechanism of Action
Age-related decline in bronchial epithelial function, environmental damage, or chronic respiratory stress
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Bronchogen | 20 mg | Once daily (evening preferred) | Typical clinical dosing for respiratory support |
| Bronchogen | 20 mg | Twice daily for first 2 weeks, then once daily | For acute respiratory recovery or severe conditions |
Safety & Contraindications
- Emerging evidence - primarily Russian clinical studies with limited international validation
- No reported toxic or allergic reactions in clinical trials
- Generally well-tolerated in clinical studies
- Safe for long-term use based on available data
- Not hormonal - works through epigenetic gene regulation
- Consult physician before use with pre-existing lung conditions
- May be contraindicated in active lung infections (theoretical)